Blind To Cancer
Other than skin cancer, prostate cancer affects more men in the U.S. than any other cancer, and nearly 30,000 men in the U.S. die of prostate cancer each year. It strikes a staggering one in six men and—until now—blind biopsies have been the standard of care once cancer of the prostate is suspected.
"With an estimated 1.5 million biopsies performed each year, conventional biopsy is blind to cancer, as 20 to 30 percent of cancers are missed and detected cancer may not be clinically relevant," says Al Barqawi, Director of Research at the University of Colorado Health Sciences Center.
"The benefits of advancements in imaging will improve our ability to accurately guide tissue sampling, improve diagnosis and manage the disease progression. We will be able to treat patients to what they have, not what we think they have."
Artemis gives the nation's nearly 10,000 urologists the technology to navigate to a desired location for prostate biopsy and record this information for future reference, treatment planning and monitoring.
This breakthrough in imaging and mapping is a major improvement over existing 2D ultrasound routinely used for prostate cancer biopsies. Without being able to clearly see the prostate in real-time, they have had no choice but to gather less-than-precise information to determine treatment.